Yuhan Corporation - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Yuhan Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Yuhan Corporation - Product Pipeline Review - 2016', provides an overview of the Yuhan Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Yuhan Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Yuhan Corporation
- The report provides overview of Yuhan Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Yuhan Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Yuhan Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Yuhan Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Yuhan Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Yuhan Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Yuhan Corporation Snapshot 6
Yuhan Corporation Overview 6
Key Information 6
Key Facts 6
Yuhan Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Yuhan Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Yuhan Corporation - Pipeline Products Glance 15
Yuhan Corporation - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Yuhan Corporation - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Yuhan Corporation - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Yuhan Corporation - Drug Profiles 19
(metformin hydrochloride SR + rosuvastatin calcium) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
bilastine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
YH-12852 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
YH-14618 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(amlodipine maleate + chlorthalidone + telmisartan) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
YH-22189 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
YH-1177 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YH-14619 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
YH-18406 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
YH-18420 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YH-24931 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
YH-25348 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
YH-25448 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
YH-25723 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
YH-BIO 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
YH-GKA 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
YH-NCE2 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
YH-NCE3 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
YH-NCE4 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
YH-siRNA1 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
YH-siRNA2 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
YH-siRNA3 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Yuhan Corporation - Pipeline Analysis 43
Yuhan Corporation - Pipeline Products by Target 43
Yuhan Corporation - Pipeline Products by Route of Administration 45
Yuhan Corporation - Pipeline Products by Molecule Type 46
Yuhan Corporation - Pipeline Products by Mechanism of Action 47
Yuhan Corporation - Recent Pipeline Updates 48
Yuhan Corporation - Dormant Projects 49
Yuhan Corporation - Company Statement 50
Yuhan Corporation - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Yuhan Corporation - Key Manufacturing Facilities 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Yuhan Corporation, Key Information 6
Yuhan Corporation, Key Facts 6
Yuhan Corporation - Pipeline by Indication, 2016 8
Yuhan Corporation - Pipeline by Stage of Development, 2016 10
Yuhan Corporation - Monotherapy Products in Pipeline, 2016 11
Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2016 12
Yuhan Corporation - Partnered Products in Pipeline, 2016 13
Yuhan Corporation - Partnered Products/ Combination Treatment Modalities, 2016 14
Yuhan Corporation - Phase III, 2016 15
Yuhan Corporation - Phase II, 2016 16
Yuhan Corporation - Phase I, 2016 17
Yuhan Corporation - Preclinical, 2016 18
Yuhan Corporation - Pipeline by Target, 2016 44
Yuhan Corporation - Pipeline by Route of Administration, 2016 45
Yuhan Corporation - Pipeline by Molecule Type, 2016 46
Yuhan Corporation - Pipeline Products by Mechanism of Action, 2016 47
Yuhan Corporation - Recent Pipeline Updates, 2016 48
Yuhan Corporation - Dormant Developmental Projects,2016 49
Yuhan Corporation, Other Locations 51
Yuhan Corporation, Subsidiaries 51
Yuhan Corporation, Key Manufacturing Facilities 52